Study questions whether MOC is worth the time
The cost of completing the American Board of Internal Medicine’s maintenance of certification program may be higher... More
Targeting H. pylori may help prevent stomach cancer
Eradicating Helicobacter pylori bacteria with a short course of antibiotics and proton pump inhibitors helped reduce... More
Drug manufacturers delayed reporting serious unexpected adverse events
Drug manufacturers did not report about 10% of serious and unexpected adverse events to the U.S. Food and Drug... More
First-time youth tobacco users turning to e-cigarettes
First-time youth tobacco users are turning to e-cigarettes, a survey showed. Researchers examining the results of the... More
FDA approves carfilzomib for relapsed multiple myeloma
The Food and Drug Administration has approved carfilzomib (Kyprolis) to be used in combination with lenalidomide... More
Dr. Richard Pazdur
Sonidegib, a hedgehog pathway inhibitor, has been approved for treating patients with locally advanced basal cell... More
Aromatase inhibitors, bisphosphonates cut postmenopausal breast cancer recurrence
Aromatase inhibitors and bisphosphonates can improve survival in postmenopausal early-stage breast cancer, and... More
Less toxic chemo for HIV-positive Burkitt lymphoma
For HIV-positive patients with Burkitt lymphoma, a modified intensive chemotherapy regimen produced overall and... More
This bone core, from a 34-year-old male, is an example of the characteristic paratrabecular infiltrate of follicular lymphoma when it involves the bone marrow. More often, the involvement is subtle and easy to overlook.
For patients with follicular lymphoma treated with a rituximab-based combination chemotherapy regimen, early disease... More
Ring sideroblast smear
Among patients with refractory anemia with ring sideroblasts, the presence of a common mutation in SF3B1 appears to be... More
Sylvia M. Burwell
As Medicare approaches its 50th anniversary next week, the federal program got some welcome financial news Wednesday:... More
Dr. Holly G. Prigerson
Palliative chemotherapy for patients with end-stage cancer who exhibit promising performance scores should be... More
AMA Town Hall: Doctors call for meaningful use delay
Stage 3 of meaningful use should be delayed until Medicare value-based care programs are developed. To move the... More
Dickkopf-3 overexpression linked to tumor traits in esophageal adenocarcinoma
Esophageal adenocarcinoma is fatal to 90% of patients, indicating a profound need for new therapeutic agents, according... More

Reviews

Ruben Guzman-Marin et al
Sleep disturbances are common among patients with cancer for many reasons. Sleep problems can be present at any stage during treatment for cancer and in some patients, sleep disturbance may be the presenting symptoms that lead to the diagnosis of som... More »
 

Reviews

Fayez Estephan et al
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms with an annual incidence of 4.1 cases per 100,000 Americans. Patients with MDS suffer from chronic cytopenias that may lead to recurrent transfusions, infections, and ... More »
 
Louise C Occomore et al
Background Our hospital did not provide a weekly speech and language therapy (SLT) service for head and neck cancer patients during radiotherapy treatment. SLT is recommended in the international guidelines, but many centers do not offer this service... More »
 
Xiaoyun Pan et al
Background The rates of depression in adults with cancer have been reported as high as 38%-58%. How depression affects overall health care expenditures in individuals with cancer is an under-researched area. Objective To estimate excess average tota... More »
 

Features

Susan London, Neil Osterweil, Patrice Wendling
Immunotherapies once again took center stage at the 2015 annual meeting of the American Society for Clinical Oncology in Chicago, though many other groundbreaking clinical advances were also presented. The meeting’s theme, “Illumination and innov... More »
 

Features

Jane de Lartigue, PhD
Lung cancer remains the single biggest cause of cancer-related mortality, responsible for nearly a quarter of all deaths.1 Although major breakthroughs in the treatment of the most common form – non-small-cell lung cancer (NSCLC) – have been hera... More »
 

From the Editor

Howard A Burris, III, MD
The 2015 annual meeting of the American Society for Clinical Oncology, themed “Illumination and innovation: transforming data into learning,” brought together more than 37,000 attendees in Chicago and featured numerous clinical advances that will... More »
 

From the Editor

David H Henry, MD, FACP
Well, what just happened in Chicago? Nearly 30,000 of our closest friends and colleagues descended on the windy city to meet in the McCormick Center to catch up on the latest data and updates in oncology at the American Society of Clinical Oncology's... More »